|Mr. Francis Gleeson B.B.A. M.B.A||Co-Founder, CEO, Pres & Director||233.33k||N/A||1955|
|Dr. Michael A. Rudnicki Ph.D.||Co-Founder & Chief Scientific Officer||98k||N/A||1961|
|Mr. Warren Whitehead C.M.A., CPA||Chief Financial Officer||46.13k||N/A||1952|
|Mr. William Wasyl Jarosz||Exec. Director||162.27k||N/A||1956|
|Mr. Michael Liggett B.Sc., Bsc. Pharm., C.A., C.P.A., CA, CPA||Strategic Advisor||44.48k||N/A||1960|
|Dr. Philip Lambert M.A., Ph.D.||Chief Technology Officer||N/A||N/A||1968|
|Mr. J. Robert Hall CFA||VP of Fin. & Admin.||N/A||N/A||N/A|
Satellos Bioscience Inc., a regenerative medicine company, develops therapeutics to treat degenerative muscle diseases. Its lead program focuses on the development of oral therapeutic drug to correct muscle stem cell polarity and restore the body's innate muscle repair and regeneration process. The company was incorporated in 2012 and is headquartered in Toronto, Canada.
Satellos Bioscience Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.